GLP-1 Receptor Agonists Special Populations: A Prescriber's Summary

What Is the GLP-1 Receptor Agonist Drug Class?

GLP-1 receptor agonists (GLP-1 RAs) are a class of incretin-based therapies that bind and activate the glucagon-like peptide-1 receptor, reproducing and amplifying the effects of endogenous GLP-1. They lower postprandial glucose by stimulating glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via central hypothalamic pathways. The net result is improved glycemic control and, at higher doses, clinically meaningful weight loss.

Mechanism at the Receptor Level

Endogenous GLP-1 has a plasma half-life of roughly 2 minutes because dipeptidyl peptidase-4 (DPP-4) degrades it rapidly. Pharmacological GLP-1 RAs are engineered to resist DPP-4 cleavage, extending half-lives from hours (exenatide immediate-release, 2.4 hours) to approximately one week (semaglutide, 165 to 184 hours) [1]. That extended half-life drives the shift from twice-daily to once-weekly dosing schedules.

Approved Agents and Their Structural Scaffolds

Six structurally distinct GLP-1 RAs have reached U.S. Approval. Exenatide (Byetta, Bydureon) is exendin-4-based and shares 53% homology with human GLP-1. Liraglutide, dulaglutide, and semaglutide are human GLP-1 analogues with fatty acid or albumin-binding modifications. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 RA, though it is frequently reviewed alongside the class.

The FDA approved liraglutide (Saxenda) for chronic weight management in 2014, semaglutide subcutaneous 2.4 mg (Wegovy) in 2021, and tirzepatide (Zepbound) for obesity in November 2023 [2].

Cardiovascular Outcomes: What the Trials Actually Show

All three major GLP-1 RA cardiovascular outcome trials demonstrated non-inferiority, and two showed superiority, for major adverse cardiovascular events (MACE) versus placebo in patients with established cardiovascular disease or high risk.

LEADER (Liraglutide)

LEADER enrolled 9,340 adults with type 2 diabetes and high CV risk. Liraglutide 1.8 mg daily reduced the primary MACE endpoint (CV death, non-fatal MI, non-fatal stroke) by 13% versus placebo (HR 0.87, 95% CI 0.78 to 0.97, P<0.001 for non-inferiority; P=0.01 for superiority) at a median follow-up of 3.8 years [3]. The benefit was driven largely by a reduction in CV mortality.

SUSTAIN-6 (Semaglutide)

SUSTAIN-6 studied 3,297 patients with type 2 diabetes and found that semaglutide 0.5 mg or 1.0 mg once weekly reduced MACE by 26% versus placebo (HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for non-inferiority) over 2.1 years [4]. Non-fatal stroke drove a disproportionate share of the benefit, a pattern not seen as strongly in LEADER.

REWIND (Dulaglutide)

REWIND enrolled 9,901 patients with type 2 diabetes, notably including a higher proportion of patients without prior cardiovascular events (31.5% primary prevention). Dulaglutide 1.5 mg weekly reduced MACE by 12% (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) over a median 5.4 years [5]. The primary-prevention subgroup finding has influenced guideline language around early cardioprotective prescribing.

The 2023 American Diabetes Association Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen" [6].

Weight Management: Efficacy Data Across Populations

STEP Program (Semaglutide 2.4 mg)

The STEP trials established semaglutide 2.4 mg subcutaneous weekly as the benchmark for pharmacological weight loss before tirzepatide data matured. In STEP-1 (N=1,961), adults with obesity (BMI ≥30 or ≥27 with a weight-related comorbidity) but without type 2 diabetes lost a mean 14.9% of body weight at 68 weeks versus 2.4% on placebo (P<0.001) [7]. Roughly 69% of semaglutide-treated patients achieved ≥10% weight loss.

STEP-2 (N=1,210), conducted in patients with type 2 diabetes, showed 9.6% mean weight loss with semaglutide 2.4 mg versus 3.4% with placebo [8]. The attenuated response in the diabetic population is consistent across the class and is attributed in part to lower baseline endogenous GLP-1 secretion and greater insulin resistance.

SURMOUNT-1 (Tirzepatide)

SURMOUNT-1 (N=2,539) tested tirzepatide 5 mg, 10 mg, and 15 mg weekly in adults with obesity without type 2 diabetes. The 15 mg dose achieved 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (P<0.001) [9]. That figure approximates outcomes seen with Roux-en-Y gastric bypass in some surgical series. Whether this dual-agonist mechanism produces durable superiority over GLP-1 monotherapy at matched tolerability is still being examined in head-to-head trials.

HealthRX Clinical Framework: Choosing Between Agents for Weight-Primary vs. Glucose-Primary Goals

When the clinical goal is primarily weight reduction in a non-diabetic patient, semaglutide 2.4 mg (Wegovy) or tirzepatide (Zepbound) are the two FDA-approved options. When glucose control is the primary goal and weight loss is secondary, once-weekly semaglutide 1 mg (Ozempic), dulaglutide 1.5 mg (Trulicity), or liraglutide 1.8 mg (Victoza) are all appropriate first-line choices depending on injection frequency preference and cost. Patients with established cardiovascular disease warrant agents with a completed CVOT showing superiority (liraglutide, semaglutide, dulaglutide). Patients with CKD and high CV risk may favor semaglutide, which showed renal-protective signals in FLOW (see renal section below).

Renal Impairment: Dosing and Safety

Most GLP-1 RAs are primarily eliminated via proteolytic degradation rather than renal clearance, which means standard renal dose adjustments are not required for the majority of the class.

Semaglutide in CKD

The FLOW trial (N=3,533) tested semaglutide 1 mg weekly in patients with type 2 diabetes and CKD (eGFR 50 to 75 at baseline). Semaglutide reduced the risk of major kidney disease events (sustained ≥50% eGFR decline, kidney failure, renal or CV death) by 24% versus placebo (HR 0.76, 95% CI 0.66 to 0.88, P<0.001) [10]. Based on these data, the FDA added a chronic kidney disease indication to semaglutide's label in 2024.

Semaglutide does not require dose adjustment for any level of renal impairment, including dialysis patients. Volume depletion from nausea and vomiting warrants monitoring in patients with eGFR <30.

Exenatide: The Exception

Exenatide immediate-release (Byetta) is eliminated by glomerular filtration and is contraindicated when eGFR <30 mL/min/1.73 m². Exenatide extended-release (Bydureon) is also not recommended below eGFR 45 [11]. Prescribers managing patients with moderate-to-severe CKD who need a GLP-1 RA should select semaglutide, dulaglutide, or liraglutide rather than either exenatide formulation.

Liraglutide and Dulaglutide in CKD

Liraglutide's renal data from LEADER showed no significant increase in adverse renal events across eGFR categories. No dose reduction is required down to eGFR 15. Dulaglutide is similarly cleared non-renally and requires no adjustment; the REWIND trial included patients with eGFR as low as 15 without dose modification [5].

Hepatic Impairment

GLP-1 RAs are not hepatically metabolized in the cytochrome P450 sense, but hepatic impairment can affect albumin binding for liraglutide and dulaglutide. Semaglutide prescribing information notes no clinically significant pharmacokinetic change in Child-Pugh A or B hepatic impairment; data in Child-Pugh C are limited [12]. Liraglutide's labeling similarly reports no dose adjustment in mild-to-moderate hepatic impairment but cautions against use in severe hepatic impairment due to limited data.

Nonalcoholic fatty liver disease (NAFLD/NASH) may be an area of evolving benefit. A phase II trial published in the New England Journal of Medicine showed liraglutide 1.8 mg daily for 48 weeks produced NASH resolution (without worsening fibrosis) in 39% of patients versus 9% on placebo (P=0.019, N=52) [13].

Pregnancy and Lactation

GLP-1 receptor agonists are contraindicated in pregnancy across all approved agents. Labeling is based on animal reproductive toxicity studies showing fetal harm at clinically relevant exposures; strong human pregnancy registry data are not yet available. The FDA classifies semaglutide as Pregnancy Category risk: "Based on animal data, may cause fetal harm" [12].

Women of reproductive potential should discontinue semaglutide at least 2 months before a planned pregnancy, given its long half-life. Liraglutide and exenatide, with shorter half-lives, have a shorter pre-conception washout requirement, but no GLP-1 RA has established safety in human pregnancy.

Lactation data are also absent for the class. Because the drugs are large peptides, oral bioavailability in a nursing infant would likely be negligible, but the absence of safety data means breastfeeding during GLP-1 RA treatment is generally not recommended.

Polycystic ovary syndrome (PCOS) represents a practical intersection: GLP-1 RAs improve insulin sensitivity and may restore ovulatory cycles in anovulatory women with PCOS and obesity, increasing the risk of unintended pregnancy. Prescribers should address contraception planning at initiation for any woman with PCOS who is not actively trying to conceive.

Pediatric Populations

Type 2 Diabetes in Adolescents

Liraglutide 1.8 mg was the first GLP-1 RA approved for pediatric type 2 diabetes (age ≥10) in the United States. The ELLIPSE trial (N=134) showed liraglutide reduced HbA1c by 0.64% versus a 0.42% increase on placebo (treatment difference -1.06%, P<0.001) over 26 weeks in adolescents aged 10 to 17 [14]. Adverse events mirrored those in adults, with nausea being the most common.

Pediatric Obesity

The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in patients aged ≥12 with obesity (BMI ≥95th percentile) in December 2022. The STEP TEENS trial (N=201) demonstrated a mean 16.1% reduction in BMI at 68 weeks with semaglutide versus a 0.6% increase in the placebo group (P<0.001) [15]. For context, 77% of semaglutide-treated adolescents achieved ≥5% BMI reduction versus 18% on placebo.

Tirzepatide's pediatric development program is underway but has not yet yielded an FDA approval for patients under 18 as of this writing.

Heart Failure

HFpEF: STEP-HFpEF

Heart failure with preserved ejection fraction (HFpEF), particularly when associated with obesity, is an emerging indication. STEP-HFpEF (N=529) enrolled patients with HFpEF (EF ≥45%) and BMI ≥30 without type 2 diabetes. Semaglutide 2.4 mg weekly for 52 weeks produced a mean 13.3% weight loss, an 8.7-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, and a 1.8 cm reduction in 6-minute walk distance compared to placebo, all statistically significant (P<0.001) [16]. No significant safety signals emerged in this population.

HFrEF Caution

The picture is less clear in heart failure with reduced ejection fraction (HFrEF). An earlier phase II trial of liraglutide in HFrEF (LIVE trial, N=241) found no improvement in left ventricular function and a higher rate of serious cardiac events in the liraglutide group (26 vs. 16 events, P=0.069), though the trial was underpowered for safety [17]. Current ADA and ACC guidance does not endorse GLP-1 RAs specifically for HFrEF, and their use in this setting warrants close monitoring.

Pancreatitis and Thyroid Risk

Pancreatitis

Acute pancreatitis is an uncommon but serious adverse event. Post-marketing reports led the FDA to add a pancreatitis warning to all GLP-1 RA labels. An FDA-led review of the LEADER and SUSTAIN-6 databases found no statistically significant increase in pancreatitis incidence versus comparators, but absolute rates in clinical trial populations are low enough that they cannot rule out a signal [18]. GLP-1 RAs are contraindicated in patients with a personal history of pancreatitis, and prescribers should discontinue them if acute pancreatitis is confirmed.

Medullary Thyroid Carcinoma

Rodent studies showed dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC) with GLP-1 RAs. This has not been confirmed in human registries to date, but the FDA requires a boxed warning, and GLP-1 RAs are contraindicated in patients with personal or family history of MTC or MEN2 syndrome [12].

Older Adults

Patients aged ≥65 years tolerate GLP-1 RAs but face specific considerations. Nausea-driven anorexia compounds the risk of sarcopenic weight loss, a concern because roughly 25 to 39% of weight lost on GLP-1 RAs is lean mass, according to DEXA substudy analyses from the STEP trials [7]. Prescribers treating older adults should consider concurrent resistance exercise programming and protein intake ≥1.2 g/kg/day to attenuate lean mass loss.

Renal function declines with age, but as described above, most agents do not require dose adjustment until eGFR drops below 30 (or 15 for semaglutide and dulaglutide). No pharmacokinetic dose adjustments are recommended solely based on age for any approved agent [11, 12].

GI Tolerability and Practical Titration

Nausea is the most common adverse event across the class, affecting 30 to 44% of patients in key trials. Vomiting occurs in 10 to 24%. Both are dose-dependent and peak during titration phases. In STEP-1, 4.5% of semaglutide-treated patients discontinued due to GI adverse events versus 0.8% on placebo [7].

Standard titration for semaglutide 2.4 mg starts at 0.25 mg weekly for 4 weeks, then escalates by 0.25 mg every 4 weeks to the maintenance dose of 2.4 mg. Slowing the titration schedule (staying at an intermediate dose for 8 weeks rather than 4) reduces nausea without meaningfully impairing long-term weight outcomes, based on clinical practice patterns supported by the prescribing information's flexibility clause [12].

Prescribers should counsel patients to eat smaller meals, avoid high-fat foods during titration, and maintain hydration. Anti-emetics (ondansetron 4 mg as needed) may be offered during the first 8 to 12 weeks if nausea limits adherence.

Drug Interactions and Oral Medications

Delayed gastric emptying reduces the rate of absorption of oral medications. This is clinically significant for drugs with narrow therapeutic windows: cyclosporine, levothyroxine, and oral hormonal contraceptives. Patients on levothyroxine should have TSH re-checked 6 to 8 weeks after GLP-1 RA initiation. Women relying on oral contraceptives for pregnancy prevention may need to switch to a non-oral method, or use a backup method during the first 4 weeks at each new dose level, as recommended in liraglutide's labeling [19].

Concurrent sulfonylurea or insulin use raises the risk of hypoglycemia, since GLP-1 RAs can reduce fasting glucose significantly. The ADA recommends reducing sulfonylurea dose by 50% or discontinuing it when adding a GLP-1 RA in most patients [6].